Travere Therapeutics Expands Market Reach with FILSPARI Approval Amid Strong Revenue Growth

Travere Therapeutics (NASDAQ: TVTX) is poised for commercial expansion following the FDA's full approval of FILSPARI for the treatment of focal segmental glomerulosclerosis (FSGS). The drug is now the sole approved therapy for this condition, significantly broadening the company's addressable U.S. market to an estimated 30,000 patients, supplementing its existing IgAN patient base. The approval coincides with a period of rapid financial acceleration. In full-year 2025, FILSPARI generated $322 million in net product sales, representing a 144% increase year-over-year. Total product sales for the period reached $410.5 million, signaling strong market adoption. Travere has successfully transitioned to profitability, reporting a non-GAAP net income of $81.1 million for 2025, a sharp reversal from the $241 million non-GAAP net loss recorded in 2024. The company maintains a solid liquidity position with $322.8 million in cash and marketable securities. Amidst this growth, Director Gary A. Lyons reduced his holdings by 12.21%, selling 8,000 shares on April 14, 2026, for approximately $329,000. The transaction, executed at a weighted average price of $41.07, occurred the day after the FDA approval announcement. Looking ahead, Travere expects a $25 million milestone payment from Mirum in the first half of 2026. Additionally, the company has resumed enrollment in its Phase 3 study for pegtibatinase in classical HCU, adding further optionality to its clinical pipeline.